ClinicalTrials.gg
TerminatedNCT03104270Updated Mar 31, 2022

Combination Study for High Risk Multiple Myeloma Patients

A Phase 2 interventional study of Elotuzumab and Pomalidomide in Multiple Myeloma, sponsored by Oncotherapeutics. Terminated at 6 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-03-31.

Sponsored by Oncotherapeutics · Phase 2, Interventional, and Treatment

Why this study was terminated
The study was terminated early by Funding Sponsor due to low enrollment.

From the registry’s dates

  • Primary completion was Oct 2019, 7 years ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
13
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 41 studies testing elotuzumab in Multiple Myeloma — 2 open to participants now, 9 under way, 2 of them phase 3. elotuzumab · Multiple Myeloma.

Enrollment
34th of 41
13 · median 40
Started
2017
with 5 others
Phase 2
25 of 41
none open now
Registered
26th of 41
by date

Among the 41 studies testing elotuzumab in Multiple Myeloma, this one is the 34th largest by enrollment, is one of 6 that started in 2017, is one of 25 in phase 2, and was the 26th registered.

Multiple Myeloma

3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

2 of the 41 studies testing elotuzumab in Multiple Myeloma are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About elotuzumab

elotuzumab: first FDA approval 2015 (EMPLICITI), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 41 studies testing elotuzumab in Multiple Myeloma, or all of them as a file.
02

Study summary

Despite the recent introduction of novel anti-multiple myeloma (MM) agents, high risk MM remains with poor prognosis and a therapeutic challenge. Elotuzumab (ELO) is a humanized monoclonal antibody that recognizes CS1/CD139, a molecule highly expressed in MM cells. The ELO (10 mg/kg), lenalidomide (LEN) and dexamethasone (DEX) combination achieves high overall response rates (ORR) and long progression-free survival (PFS) for patients with relapsed/refractory disease (RR) MM and those with impaired renal function. However, its efficacy for MM patients with high risk characteristics is still unknown. Pomalidomide (POM) is a recently approved immunomodulatory agent (IMiD) that produces response rates for high-risk RRMM patients when used in combination with DEX and other agents, including the proteasome inhibitor (PI) bortezomib (BTZ). POM has also demonstrated activity for LEN refractory patients. Carfilzomib (CFZ) is a potent second generation PI that has shown to be efficacious for IMiD and BTZ refractory patients as well as high risk patients carrying cytogenetic abnormalities. In this study, we propose to evaluate efficacy and safety of ELO in combination with POM, DEX and CFZ for high-risk RRMM patients.

Read the detailed description

This is a Phase 2, multicenter, open label, nonrandomized study with six patients safety lead-in cohort to evaluate efficacy and safety of elotuzumab in combination with pomalidomide, carfilzomib and dexamethasone among high risk relapsed and refractory multiple myeloma patients.

This study will enroll previously treated patients that currently show evidence of progressive disease and have been diagnosed with high risk multiple myeloma. Thirty-nine patients will be enrolled in the study.

First, six patients will be enrolled and used as a lead-in cohort for the safety evaluation and MTD re-determination (if necessary). The results of the safety lead-in cohort will be evaluated after the 6th patient has completed one full cycle of treatment. Recruitment of patients will be withheld during safety data analysis. Enrollment of the remaining 33 patients will be contingent upon safety committee's decision.

The study consists of: 1) a screening period; 2) up to eight 28-day treatment cycles; 3) a final assessment to occur 28 days after the end of the last treatment cycle; and 4) a follow-up period.

All drugs will be administered on a 28-day cycle schedule throughout the study. Subjects eligible for this study will receive treatment with study drug for a maximum of eight 28-day treatment cycles. Subjects are to be treated for 8 cycles of therapy without demonstrating PD.

03

Conditions studied

  • Multiple Myeloma

Browse trials for

Keywords

  • Elotuzumab, Multiple Myeloma, Phase 2
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects must be adults (age ≥ 18 years at the time of signing the document) and must meet all of the following inclusion criteria to be enrolled in the study:

    1. /Zubrod performance status of 0-2 at study entry
    2. Has a diagnosis of high-risk MM by showing any of the following a-f criteria: :

      1. Presence of conventional cytogenetic markers such as deletion of 17p-p53, translocations involving t(14;16) and t(14;20)
      2. Plasma cell leukemia (PCL) (> 2.0 × 109/L circulating plasma cells by standard differential)
      3. Extramedullary MM
      4. Doubling in levels of a MM markers in the past 3 months such as any of the following criteria alone or in combination: i) Serum M-protein ≥ 1.0 g/dL, or ii) Urine M-protein ≥ 400 mg/24 hours, or iii) Only in patients who do not meet i or ii, then use serum free light chain (SFLC) > 200 mg/L (involved light chain) and an abnormal kappa/lambda ratio
      5. Refractoriness to their most recent lenalidomide-containing regimen and proteasome inhibitor-containing regimen.
      6. Renal failure related to MM with (CrCl) >15 mL/min but \<30 mL/min as calculated by Cockcroft-Gault equation (Appendix 14.8).
    3. Has previously received more than two including a lenalidomide-containing regimen and proteasome inhibitor-containing regimen.
    4. Currently demonstrating progressive disease
    5. greater than 3 months
    6. Laboratory test results within these ranges at Screening and confirmed at enrollment prior to drug dosing on Cycle 1 Day 1:

      • ≥ 1.5 x 109/L; if the bone marrow is extensively infiltrated ( ≥ 70% plasma cells) then ≥ 1.0 x 109/L
      • count ≥ 75 x 109/L; if the bone marrow is extensively infiltrated ( ≥ 70% plasma cells) then ≥ 50 x 109/L
      • ≥ 8 g/dL
    7. Women of (WOCBP†) must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG) within 10-14 days prior to and again within 24 hours of starting study drug regimen

      † A WOCBP (women of childbearing potential) is a sexually mature woman who: 1) has not undergone a hysterectomy or bilateral oophorectomy; or 2) has not been naturally for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months) WOCBP must agree to follow instructions for method(s) of for the duration of treatment with study drug (s) plus 5 half-lives of study drug plus 30 days (duration of ovulatory cycle) for a total of 120 days post-treatment completion. Subject must either commit to continued abstinence from heterosexual intercourse or begin TWO acceptable methods of birth control, one highly effective method and one additional effective method AT THE SAME TIME, and at least 28 days before she starts taking study drugs. WOCBP must also agree to ongoing pregnancy testing. All subjects must be counseled at a minimum of every 28 days about pregnancy precautions and risks of fetal exposure. See Section 10.3.5.2, Appendix 4 and Appendix 5. Males who are sexually active with WOCBP must agree to follow instructions for method(s) of contraception for the duration of treatment with study drug plus 5 half-lives of the study drug plus 90 days (duration of sperm turnover) for a total of 154 days post-treatment completion. Men must agree to use a latex condom during sexual contact with a WOCBP even if they have had a vasectomy. All subjects must be counseled at a minimum of every 28 days about pregnancy precautions and risks of fetal exposure. See Section 10.3.5, Appendix 4 and Appendix 5

    8. Able to take aspirin (acetylsalicylic acid, ASA) at 81 or 325 mg/daily as prophylactic anticoagulation (subjects intolerant to ASA may use warfarin or low molecular weight heparin)
    9. Written informed consent in accordance with federal, local, and institutional guidelines
    10. Able to adhere to the study visit schedule and other protocol requirements

Exclusion criteria

Exclusion Criteria:

  • Subjects meeting any of the following exclusion criteria are not to be enrolled in the study:

    1. POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes) 19
    2. Waldenström's macroglobulinemia
    3. Received the following prior therapy:

      1. Elotuzumab
      2. Chemotherapy within 3 weeks of study drugs (6 weeks for nitrosourea, melphalan or monoclonal antibodies)
      3. (>10 mg/daily prednisone or equivalent) within 3 weeks of study drugs
      4. Immunomodulatory therapy within one week before study drugs
      5. Antibody therapy within 3 weeks before study drugs
      6. Extensive radiation therapy (total maximum radiation doses of 50Gy to any individual site or 30Gy for the disseminated MM of bone) within 3 weeks before study drugs. Receipt of localized radiation therapy does not preclude enrollment.
      7. Cytotoxic chemotherapy with approved or anticancer therapeutics within 3 weeks prior to first dose
      8. Use of any other experimental drug or therapy within 3 weeks of study drugs
    4. Received the following transplant therapies:

      1. Less than 12 weeks from auto transplant
      2. Less than 16 weeks from allo transplant
      3. Less than 4 weeks since any plasmapheresis
    5. Major surgery within 4 weeks prior to first dose
    6. Impaired cardiac function or cardiac diseases, including any one of the following:

      1. Myocardial infarction within last 6 months prior to enrollment
      2. Active congestive heart failure ( (NYHA) Class III or IV) heart failure
      3. Uncontrolled angina and/or hypertension
      4. Clinically significant pericardial disease
      5. Severe uncontrolled ventricular arrhythmias
      6. Echocardiogram or evidence of LVEF below institutional normal within 28 days prior to enrollment
      7. Electrocardiographic evidence of acute ischemia or active conduction system abnormalities. Prior to study entry, any abnormality at Screening has to be documented by the investigator as not medically relevant.
    7. Known or suspected amyloidosis
    8. Severe hypercalcemia, i.e., serum calcium ≥ 12 mg/dL (3.0 mmol/L) corrected for albumin
    9. Acute active infection requiring systemic antibiotics, antiviral), or antifungal agents
    10. Known positivity for (HIV)
    11. Known active hepatitis A,B or C virus infection
    12. Known active tuberculosis (TB) including subjects with latent TB or with the risk factor for activation of latent TB.
    13. Patients with known cirrhosis
    14. Secondary non-hematologic within the past 3 years, except:

      1. Adequately treated basal cell or squamous cell skin cancer
      2. Carcinoma in situ of the cervix
      3. Prostate cancer \< Gleason score 6 or less with stable prostate-specific antigen (PSA) levels over 12 months
      4. Breast carcinoma in situ with full surgical resection
      5. Treated medullary or papillary thyroid cancer
    15. Patients with myelodysplastic syndrome
    16. Prior cardio vascular accident (CVA) with persistent neurological deficit
    17. Significant neuropathy (Grades 3 to 4) within 14 days prior to first dose
    18. Peripheral neuropathy with pain ≥ G2 within 14 days prior to first dose
    19. Women who are pregnant and/or breast feeding
    20. Known to dexamethasone
    21. Known history of allergy to Captisol® (a cyclodextrin derivative used to solubilize carfilzomib)
    22. Known hypersensitivity to compounds of similar chemical or biological composition to thalidomide
    23. The development of erythema nodosum if characterized by a desquamating rash while taking thalidomide or similar drugs
    24. Hypersensitivity to any of the required concomitant drugs or supportive treatments, including hypersensitivity to antiviral drugs.
    25. Ongoing .
    26. Pleural effusions requiring thoracentesis or ascites requiring paracentesis within 14 days prior to enrollment.
    27. Uncontrolled diabetes within 2 weeks prior to enrollment.
    28. Any other clinically significant medical disease or psychiatric condition that, in the Investigator's opinion, may interfere with protocol adherence or a patient's ability to give
Terms in these criteria, in plain language(21)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
13 participants (actual)

Study arms

  • Experimental
    Elo Pom Car and Dex

    Drug dosing and administration: All drugs are administered on a 28-day cycle. Elotuzumab: 10 mg/kg IV on Days 1,8,15 and 22 Cycles 1 and 2. 20 mg/kg on Day 1 of Cycles 3 and beyond. Pomalidomide: 3 mg PO on days 1-21 Carfilzomib: 20 mg/m2 IV on days 1 of cycle 1. 56 mg/m2 IV on days 8 and 15 of cycle 1 and Days 1, 8 and 15 of the remaining seven cycles. Dexamethasone: On days 1,8,15,22 of Cycle 1-2 and day 1 of Cycle 3 and every day 1 thereafter, pre-treatment with 28 mg PO 3-24 hours prior to the start of ELO. On days 8,15,22 of Cycle 3 and beyond, 40mg of DEX PO or IV. On Day 8 and 15 of Cycle 3 and beyond, pre-treatment with DEX 40mg PO or IV at least 30 min and no more than 4 hours prior to the start of CFZ.

    Drug: Elotuzumab · Drug: Pomalidomide · Drug: Carfilzomib · Drug: Dexamethasone

Interventions

  • Elotuzumab IV at 10mg/kg Elotuzumab IV at 20mg/kg

    Also known as: BMS-901608

  • Pomalidomide PO at 3mg

    Also known as: CC-4047, Pomalyst

  • Carfilzomib 20mg/m2 IV Carfilzomib 56mg/m2 IV

    Also known as: Kyprolis

  • Dexamethasone 28mg PO Dexamethasone 40mg PO or IV Dexamethasone 8mg IV

    Also known as: Steroid

06

What researchers measure

Primary outcomes

  1. Incidence of Treatment-Emergent Adverse Events (Safety and Tolerability)

    Occurrence of adverse events throughout the study, graded via Common Terminology Criteria for Adverse Events (CTCAE) v 4.03 criteria (If necessary re-define MTD via the number of dose-limiting toxicities (DLTs) per dose level, of elotuzumab in combination with pomalidomide, carfilzomib and dexamethasone for high risk RRMM patients (based on six patients lead-in cohort if necessary).

    Time frame: 34 Months

  2. Overall Rate of Response (Efficacy)

    Efficacy of treatment will be assessed by the Overall response rate (ORR) \[ORR=complete response (CR†) + very good partial response (VGPR) + partial response (PR)\] Clinical benefit rate (CBR) \[CBR=CR† + VGPR + PR + minor response (MR)\].

    Time frame: 34 Months

Secondary outcomes

  1. PFS

    Progression-free survival (PFS): time from initiation of therapy to progressive disease or death from any cause, whichever comes first

    Time frame: 34 Months

  2. DOR

    Duration of response (DOR): time from the first response (\> PR) to progressive disease

    Time frame: 34 Months

  3. OS

    Overall survival (OS): time from initiation of therapy to death from any cause or last follow-up visit.

    Time frame: 34 Months

07

Study locations

6 sites
  • California Cancer Associates for Research & Excellence (cCARE)
    Encinitas, California 92024, United States
  • Robert A. Moss, MD, FACP, Inc
    Fountain Valley, California 92708, United States
  • Pacific Cancer Care
    Monterey, California 93940, United States
  • James Berenson, MD, Inc
    West Hollywood, California 90069, United States
  • Millennium Oncology Research Clinic
    Pembroke Pines, Florida 33024, United States
  • Regional Cancer Care Associates MD LLC
    Bethesda, Maryland 20817, United States
08

References and documents

Publications

  • Yashar D, Spektor TM, Martinez D, Ghermezi M, Swift RA, Eades B, Schwartz G, Eshaghian S, Lim S, Vescio R, Berenson JR. A phase 2 trial of the efficacy and safety of elotuzumab in combination with pomalidomide, carfilzomib and dexamethasone for high-risk relapsed/refractory multiple myeloma. Leuk Lymphoma. 2022 Apr;63(4):975-983. doi: 10.1080/10428194.2021.2005044. Epub 2021 Nov 24. PubMed 34818965 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2017 to primary completion in Oct 2019, 31 months.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 27, 2017
First posted
Apr 7, 2017
StartActual
Mar 13, 2017
Primary completionActual
Oct 25, 2019
CompletionActual
Jan 23, 2020
Last update
Mar 31, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 31, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03104270
Lead sponsor
Oncotherapeutics
Responsible party
Sponsor
First posted
Apr 7, 2017
Start date
Mar 13, 2017
Primary completion
Oct 25, 2019
Completion
Jan 23, 2020
Last update
Mar 31, 2022

Study contacts

James R Berenson, MD
principal investigator · Oncotherapeutics

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Elotuzumab · Pomalidomide · Carfilzomib · Dexamethasone

Start the discussion